drugset / Trial / NCT00310817
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
RandomizedDouble-blindPrevention
Summary
To compare the functional immune response 28 days after administration of one dose of Men ACWY-CRM conjugate vaccine without adjuvant (MenACWY-CRM(Ad-)) with that of a Men ACWY polysaccharide (PS) vaccine
Timeline
- Start
- 2005-03
- Primary completion
- 2006-05
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MenACWY polysaccharide vaccine | Vaccine | — | — |
| Subject | MenACWY-CRM conjugate vaccine, adjuvanted | Vaccine | — | — |
| Subject | MenACWY-CRM conjugate vaccine, unadjuvanted | Vaccine | — | — |